Miracogen, a Shanghai biopharma with clinical-stage antibody drug conjugates, acquired non-exclusive rights to two ADC technologies developed by Dutch biotech Synaffix in a $125 million deal. Synaffix says the two technologies, GlycoConnect™ and HydraSpace™, create ADCs with enhanced efficacy and tolerability. Miracogen, which licensed the technologies for use in its next clinical candidate, will make upfront and potential milestone payments that total $125 million, plus royalties.
Source: China Biotoday